Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27813567 | 0.87 | TGFBR1 (0.36) | TGFBR1DPP4PREPFAP | |
| SCHEMBL4007514 | 0.79 | CACNA1H (0.38) | KCNH2SIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL3522643 | 0.78 | CKS1B (0.43) | KCNH2SIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL4194567 | 0.75 | IDO1 (0.33) | — | |
| SCHEMBL124646 | 0.74 | TGFBR1 (0.55) | TGFBR1 | |
| SCHEMBL5560105 | 0.74 | ENPP2 (0.32) | — | |
| SCHEMBL26330668 | 0.73 | MGLL (0.64) | MGLL | |
| SCHEMBL6485343 | 0.73 | DPP8 (0.32) | — | |
| SCHEMBL4014367 | 0.72 | SIRT2 (0.40) | SIRT2SIRT1SIRT3 | |
| SCHEMBL5995181 | 0.72 | DPP4 (0.40) | MGLLTGFBR1DPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645774-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-7071213-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050282861-A1 | Cannabinoid receptor ligands | MERCK SHARP & DOHME CORP. | 2005-12-22 | — | — | US | disclosed |
| EP-1444203-A1 | CANNABINOID RECEPTOR LIGANDS | Schering Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040010013-A1 | Piperidine derivatives used in treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases | SCHERING CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2003042174-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010013-A1 | Piperidine derivatives used in treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases | IL5, IL2, TLR1 | MGLL 3684/4885TGFBR1 782/4885DPP4 985/4885 |
| US-20050282861-A1 | Cannabinoid receptor ligands | CNR1, CNR2, GPR18 | MGLL 242/4885TGFBR1 662/4885DPP4 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.